Trial Profile
A phase III study of Alemtuzumab in patients with primary progressive multiple sclerosis (PPMS)
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 09 Feb 2018
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 07 Feb 2018 According to a Sanofi media release, the company expects to initiate this study in H2 2018.
- 18 Dec 2017 New trial record
- 13 Dec 2017 According to a Sanofi media release, the company expects to initiate this study in 2018.